Filgotinib Reduces Flare Risk in Uveitis in Phase 2 Study

Phase 2 data on filgotinib show a reduction in risk of flare in patients with uveitis and good tolerance in one of the first studies of a JAK inhibitor in uveitis.

Related Keywords

Japan ,Netherlands ,United Kingdom ,Belgium ,Robin Besuyen ,Filgotinib Jyseleca ,Xenofon Baraliakos ,Gilead Sciences ,European Union ,Drug Administration ,Ruhr University Bochum Germany ,International Congress On Spondyloarthritides ,International Congress ,Ruhr University Bochum ,Double Blind Trial ,Very Few ,Treatment Failure Favored Filgotinib ,Uveitis ,Intraocular Inflammation ,Rheumatoid Arthritis ,A ,Blindness ,Posterior Uveitis ,Sarcoidosis ,Arcoid ,Esnier Boeck Disease ,Glucocorticosteroids ,Tolerance ,Ulcerative Colitis ,Activism ,Activist ,Anti Tnf ,Anti Tumor Necrosis Factor ,Biologic Therapy ,Vision Care And Maintenance ,Immunomodulator ,Lenalidomide ,Optometry ,Social Issues ,Visual Acuity ,